Impax Asset Management Group plc Invests $2.98 Million in Insulet Corporation $PODD

Impax Asset Management Group plc acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 9,667 shares of the medical instruments supplier’s stock, valued at approximately $2,984,000.

Several other hedge funds have also added to or reduced their stakes in PODD. Sage Mountain Advisors LLC increased its holdings in shares of Insulet by 4.6% during the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after acquiring an additional 33 shares in the last quarter. Curi Capital LLC lifted its stake in shares of Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after buying an additional 36 shares in the last quarter. Evelyn Partners Investment Management Services Ltd increased its position in shares of Insulet by 28.7% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock valued at $55,000 after acquiring an additional 39 shares in the last quarter. PDS Planning Inc raised its holdings in Insulet by 5.1% in the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock worth $253,000 after acquiring an additional 40 shares during the last quarter. Finally, Camarda Financial Advisors LLC lifted its position in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares in the last quarter.

Insulet Trading Down 0.6%

Shares of PODD stock opened at $250.85 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. The stock has a fifty day simple moving average of $279.92 and a two-hundred day simple moving average of $307.07. The firm has a market capitalization of $17.65 billion, a PE ratio of 72.71, a PEG ratio of 1.43 and a beta of 1.41. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $354.88.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Raymond James Financial upped their price target on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Leerink Partners boosted their price objective on shares of Insulet from $385.00 to $386.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Royal Bank Of Canada raised their target price on shares of Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Wolfe Research increased their price target on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, Evercore initiated coverage on Insulet in a report on Tuesday, December 16th. They issued an “outperform” rating and a $370.00 price objective for the company. Twenty research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.